Bold text indicates members of the lab, and (*) indicate co-corresponding authorship.

Immune Checkpoints in the Heart

Ma P, Liu J, Qin J, Lai L, Heo GS, Luehmann H, Sultan D, Bredemeyer A, Bajapa G, Feng G, Jimenez J, He R, Parks A, Amrute J, Villanueva A, Liu Y, Lin CY, Mack M, Amancherla K, Moslehi J*, Lavine KJ*. Expansion of Pathogenic Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis. Circulation. 2024 Jan 2;149(1):48-66. doi: 10.1161/CIRCULATIONAHA.122.062551. Epub 2023 Sep 25. PMID: 37746718.

Fenioux C, Abbar B, Boussouar S, Bretagne M, Power JR, Moslehi JJ, Gougis P, Amelin D, Dechartres A, Lehmann LH, Courand PY, Cautela J, Alexandre J, Procureur A, Rozes A, Leonard-Louis S, Qin J; International ICI-Myocarditis Registry; Cheynier R, Charmeteau-De Muylder B, Redheuil A, Tubach F, Cadranel J, Milon A, Ederhy S, Similowski T, Johnson DB, Pizzo I, Catalan T, Benveniste O, Hayek SS, Allenbach Y, Rosenzwajg M, Dolladille C, Salem JE*. Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis. Nat Med. 2023 Dec;29(12):3100-3110. doi: 10.1038/s41591-023-02591-2. Epub 2023 Oct 26. Erratum in: Nat Med. 2023 Nov 27;: Erratum in: Nat Med. 2024 Jan 3;: PMID: 37884625.

Ammirati E*, Moslehi JJ*. Diagnosis and Treatment of Acute Myocarditis: A Review. JAMA. 2023 Apr 4;329(13):1098-1113. doi: 10.1001/jama.2023.3371. PMID: 37014337.

Amancherla K, Qin J, Hulke ML, Pfeiffer RD, Agrawal V, Sheng Q, Xu Y, Schlendorf KH, Lindenfeld J, Shah RV, Freedman JE, Tucker NR, Moslehi J*. Single-Nuclear RNA Sequencing of Endomyocardial Biopsies Identifies Persistence of Donor-Recipient Chimerism With Distinct Signatures in Severe Cardiac Allograft Vasculopathy. Circ Heart Fail. 2023 Jan;16(1):e010119. doi: 10.1161/CIRCHEARTFAILURE.122.010119. Epub 2022 Dec 16. PMID: 36524467; PMCID: PMC9852032.

Axelrod ML, Meijers WC, Screever EM, Qin J, Carroll MG, Sun X, Tannous E, Zhang Y, Sugiura A, Taylor BC, Hanna A, Zhang S, Amancherla K, Tai W, Wright JJ, Wei SC, Opalenik SR, Toren AL, Rathmell JC, Ferrell PB, Phillips EJ, Mallal S, Johnson DB, Allison JP, Moslehi JJ*, Balko JM*. T cells specific for α-myosin drive immunotherapy-related myocarditis. Nature. 2022 Nov;611(7937):818-826. doi: 10.1038/s41586-022-05432-3. Epub 2022 Nov 16. PMID: 36385524; PMCID: PMC9930174.

Spetz JKE, Florido MHC, Fraser CS, Qin X, Choiniere J, Yu SJ, Singh R, Friesen M, Rubin LL, Salem JE, Moslehi JJ*, Sarosiek KA*. Heightened apoptotic priming of vascular cells across tissues and life span predisposes them to cancer therapy-induced toxicities. Sci Adv. 2022 Nov 11;8(45):eabn6579. doi: 10.1126/sciadv.abn6579. Epub 2022 Nov 9. PMID: 36351019; PMCID: PMC9645721.

Zhang Y, Sun C, Li Y, Qin J, Amancherla K, Jing Y, Hu Q, Liang K, Zhang Z, Ye Y, Huang LA, Nguyen TK, Egranov SD, Zhao Z, Wu A, Xi Y, Yao J, Hung MC, Calin GA, Cheng J, Lim B, Lehmann LH, Salem JE, Johnson DB, Curran MA, Yu D, Han L, Darabi R, Yang L*, Moslehi JJ*, Lin C*. Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis. Sci Transl Med. 2022 Nov 2;14(669):eabo1981. doi: 10.1126/scitranslmed.abo1981. Epub 2022 Nov 2. PMID: 36322628; PMCID: PMC9809130.

Baik AH, Oluwole OO, Johnson DB, Shah N, Salem JE, Tsai KK, Moslehi JJ*. Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies. Circ Res. 2021 May 28;128(11):1780-1801. doi: 10.1161/CIRCRESAHA.120.315894. Epub 2021 May 3. PMID: 33934609; PMCID: PMC8159878.

Wei SC, Meijers WC, Axelrod ML, Anang NAS, Screever EM, Wescott EC, Johnson DB, Whitley E, Lehmann L, Courand PY, Mancuso JJ, Himmel LE, Lebrun-Vignes B, Wleklinski MJ, Knollmann BC, Srinivasan J, Li Y, Atolagbe OT, Rao X, Zhao Y, Wang J, Ehrlich LIR, Sharma P, Salem JE, Balko JM, Moslehi JJ*, Allison JP*. A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention. Cancer Discov. 2021 Mar;11(3):614-625. doi: 10.1158/2159-8290.CD-20-0856. Epub 2020 Nov 30. PMID: 33257470; PMCID: PMC8041233.

Moslehi J, Lichtman AH, Sharpe AH, Galluzzi L, Kitsis RN*. Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms. J Clin Invest. 2021 Mar 1;131(5):e145186. doi: 10.1172/JCI145186. PMID: 33645548; PMCID: PMC7919710.

Salem JE, Allenbach Y, Vozy A, Brechot N, Johnson DB, Moslehi JJ, Kerneis M*. Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis. N Engl J Med. 2019 Jun 13;380(24):2377-2379. doi: 10.1056/NEJMc1901677. PMID: 31189043.

Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, Gobert A, Spano JP, Balko JM, Bonaca MP, Roden DM, Johnson DB*, Moslehi JJ*. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018 Dec;19(12):1579-1589. doi: 10.1016/S1470-2045(18)30608-9. Epub 2018 Nov 12. PMID: 30442497; PMCID: PMC6287923.

Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB*. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018 Mar 10;391(10124):933. doi: 10.1016/S0140-6736(18)30533-6. PMID: 29536852; PMCID: PMC6668330.

Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, Becker JR, Slosky DA, Phillips EJ, Pilkinton MA, Craig-Owens L, Kola N, Plautz G, Reshef DS, Deutsch JS, Deering RP, Olenchock BA, Lichtman AH, Roden DM, Seidman CE, Koralnik IJ, Seidman JG, Hoffman RD, Taube JM, Diaz LA Jr, Anders RA, Sosman JA*, Moslehi JJ*. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med. 2016 Nov 3;375(18):1749-1755. doi: 10.1056/NEJMoa1609214. PMID: 27806233; PMCID: PMC5247797.

Kinase Signaling

Salem JE, Manouchehri A, Bretagne M, Lebrun-Vignes B, Groarke JD, Johnson DB, Yang T, Reddy NM, Funck-Brentano C, Brown JR, Roden DM, Moslehi JJ*. Cardiovascular Toxicities Associated With Ibrutinib. J Am Coll Cardiol. 2019 Oct 1;74(13):1667-1678. doi: 10.1016/j.jacc.2019.07.056. PMID: 31558250.

Brown JR, Moslehi J, O'Brien S, Ghia P, Hillmen P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Kipps TJ, Coutre S, Dilhuydy MS, Cramer P, Tedeschi A, Jaeger U, Dreyling M, Byrd JC, Howes A, Todd M, Vermeulen J, James DF, Clow F, Styles L, Valentino R, Wildgust M, Mahler M, Burger JA*. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017 Oct;102(10):1796-1805. doi: 10.3324/haematol.2017.171041. Epub 2017 Jul 27. PMID: 28751558; PMCID: PMC5622864.

Lampson BL, Yu L, Glynn RJ, Barrientos JC, Jacobsen ED, Banerji V, Jones JA, Walewska R, Savage KJ, Michaud GF, Moslehi JJ, Brown JR*. Ventricular arrhythmias and sudden death in patients taking ibrutinib. Blood. 2017 May 4;129(18):2581-2584. doi: 10.1182/blood-2016-10-742437. Epub 2017 Feb 21. PMID: 28223277; PMCID: PMC7219062.

Moslehi JJ*. Cardiovascular Toxic Effects of Targeted Cancer Therapies. N Engl J Med. 2016 Oct 13;375(15):1457-1467. doi: 10.1056/NEJMra1100265. PMID: 27732808.

Groarke JD, Cheng S, Moslehi J*. Cancer-drug discovery and cardiovascular surveillance. N Engl J Med. 2013 Nov 7;369(19):1779-81. doi: 10.1056/NEJMp1313140. Epub 2013 Nov 1. PMID: 24180496.

HIF, Prolyl Hydroxylases and the Heart

Olenchock BA, Moslehi J, Baik AH, Davidson SM, Williams J, Gibson WJ, Chakraborty AA, Pierce KA, Miller CM, Hanse EA, Kelekar A, Sullivan LB, Wagers AJ, Clish CB, Vander Heiden MG, Kaelin WG Jr. EGLN1 Inhibition and Rerouting of α-Ketoglutarate Suffice for Remote Ischemic Protection. Cell. 2016 Feb 25;164(5):884-95. doi: 10.1016/j.cell.2016.02.006. Erratum in: Cell. 2016 Apr 7;165(2):497. PMID: 26919427; PMCID: PMC4819986.

Moslehi J, Minamishima YA, Shi J, Neuberg D, Charytan DM, Padera RF, Signoretti S, Liao R, Kaelin WG Jr. Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy. Circulation. 2010 Sep 7;122(10):1004-16. doi: 10.1161/CIRCULATIONAHA.109.922427. Epub 2010 Aug 23. PMID: 20733101; PMCID: PMC2971656.